MRVL’s 5.1% Drop: Cautious Buy on Growth at a Lower Price

I see no supplied fundamental evidence that justifies a fresh 5.13% markdown today, though the broader correction is substantial: MRVL is down 35.3% in one month and sits 50.7% below its 52-week high. The high 2.33 beta makes sharp moves unsurprising, so I cannot call one session a clear overreaction. Operating data remain strong: Q3 revenue rose 36.5% year over year, net income 58.1%, and net margin improved 1.5 percentage points to 11.2%; however, free cash flow grew a slower 14.8%. Valuation still demands execution at 50.7x trailing earnings, but falls to 21.2x consensus FY2027 EPS of $7.350, forecast up 74.2%. I’m modestly buying the dip, while recognizing forecast and cycle risk; today’s move does not overturn my view.